TrialCNS drugs2020

A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects.

Michael J Fossler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.